Aktis Oncology Inc. shares jumped 50% in their trading debut after the clinical-stage biotechnology company raised $317.7 million in an initial public offering. Shares of the Boston-based firm opened at $27 per share on Friday in New York, versus an IPO price of $18 apiece. The offering of 17.65 million was marketed in a range of $16 to $18 each, and was increased from 11.8 million shares earlier ...
Aktis Oncology Inc. shares jumped 50% in their trading debut after the clinical-stage biotechnology company raised $317.7 million in an initial public offering. Shares of the Boston-based firm opened at $27 per share on Friday in New York, versus an IPO price of $18 apiece. The offering of 17.65 million was marketed in a range of $16 to $18 each, and was increased from 11.8 million shares earlier in the week. The listing also drew interest from existing backer Eli Lilly & Co. for about $100 million shares, according to an earlier filing . Friday’s trading gives Aktis a market value of about $1.4 billion, based on the outstanding shares listed in the filing. Aktis’ listing comes amid a busy slate of possible debuts in the first months of 2026. Diabetes-management firm MiniMed Group Inc. is planning a public listing following its separation from health-care giant Medtronic Plc , while construction-equipment rental company EquipmentShare.com Inc. and Arko Petroleum Corp. filed for IPOs in December. Aktis entered an agreement with Eli Lilly in 2024 to develop anti-cancer radiopharmaceuticals, according to its filings. As part of the deal, Aktis received $60 million in cash upfront from Eli Lilly and stands to potentially earn another $1.2 billion as certain research, regulatory and commercial launch milestones are met. Founded in 2021, Aktis is focused on developing targeted therapies that use alpha-emitting radioactive agents to treat solid tumors. The company incurred a net loss of $48.6 million on revenue of $4.6 million for the nine months ended Sept. 30, compared with a net loss of $31.9 million on revenue of $554,000 a year earlier, the filings show. Aktis has raised approximately $346 million from leading life-sciences institutional investors including MPM BioImpact, Vida Ventures, EcoR1 Capital and Blue Owl Capital. Affiliates of MPM were expected to have 17% of Aktis shares after the IPO, while Vida has 9.5%, EcoR1 7% and Blue Owl 4.6%, according to the filings...
The holidays aren't just a time for people to celebrate. Holidays are a time for the markets to celebrate, too. The " Santa Claus rally ," which looks at the performance of the S&P 500 (SNPINDEX: ^GSPC) over the last five trading days of December and the first two of January, is traditionally considered a good opportunity for investors to capture gains. From 1950-2025, the S&P 500 has posted posit...
The holidays aren't just a time for people to celebrate. Holidays are a time for the markets to celebrate, too. The " Santa Claus rally ," which looks at the performance of the S&P 500 (SNPINDEX: ^GSPC) over the last five trading days of December and the first two of January, is traditionally considered a good opportunity for investors to capture gains. From 1950-2025, the S&P 500 has posted positive returns 78% of the time during this period, with an average gain of 1.3%. However, the rally ending in 2026 delivered a warning, not tidings of good cheer. Continue reading
If you had made an investment of $1,000 in shares of Nebius Group (NASDAQ: NBIS) a year ago, that position would now be worth more than $3,200. The stock's stunning surge during this period was the result of terrific growth in its revenue, as well as a fast-improving pipeline that points toward a significant acceleration in growth from here. The remarkable results that Nebius has been clocking in ...
If you had made an investment of $1,000 in shares of Nebius Group (NASDAQ: NBIS) a year ago, that position would now be worth more than $3,200. The stock's stunning surge during this period was the result of terrific growth in its revenue, as well as a fast-improving pipeline that points toward a significant acceleration in growth from here. The remarkable results that Nebius has been clocking in recent quarters aren't surprising. Nebius is a neocloud provider that offers full-stack artificial intelligence (AI) infrastructure services to customers. Nebius operates dedicated AI data centers equipped with high-end graphics processing units ( GPUs ) that customers can rent to train and run their AI models. Even better, it offers software services and tools along with computing capacity to enable its clients to develop and deploy AI applications. This integrated approach of providing an end-to-end hardware and software AI development platform has been a hit with customers. But can Nebius sustain its remarkable growth in the long run and deliver enough gains to turn today's retail investors into millionaires? Continue reading
(RTTNews) - New residential construction in the U.S. saw a steep drop in the month of October, according to a report released by the Commerce Department on Friday.
(RTTNews) - New residential construction in the U.S. saw a steep drop in the month of October, according to a report released by the Commerce Department on Friday.
United Wholesale Mortgage at the NYSE, January 22, 2021 Source: The New York Stock Exchange Shares in mortgage lenders jumped Friday after President Donald Trump instructed "representatives" to purchase mortgage bonds in an attempt to lower rates for homebuyers . Trump said in a social media post on Thursday that he was asking unnamed buyers — it wasn't clear if that meant the Treasury, Fannie Mae...
United Wholesale Mortgage at the NYSE, January 22, 2021 Source: The New York Stock Exchange Shares in mortgage lenders jumped Friday after President Donald Trump instructed "representatives" to purchase mortgage bonds in an attempt to lower rates for homebuyers . Trump said in a social media post on Thursday that he was asking unnamed buyers — it wasn't clear if that meant the Treasury, Fannie Mae, Freddie Mac or another agency — to buy $200 billion of mortgage bonds. This should bring down both rates and monthly payments, making home ownership more affordable, Trump said. Federal Housing Finance Agency Director Bill Pulte later posted that "we are on it." Trump said he was making the push because Fannie and Freddie — the government-sponsored entities that buy mortgages from banks, credit unions and other original lenders — are sitting on a pile of cash. Mortgage lender Rocket Companies jumped more than 6% to a fresh 52-week high. UWM Holdings gained more than 8%, on track for one of its best sessions in the past year. Lender PennyMac rose about 5%. Artificial intelligence-focused lender Better Home & Finance added more than 2%. Opendoor Technologies , a real estate ecommerce platform that has become a meme stock, surged more than 16%. Stock Chart Icon Stock chart icon Rocket and UWM, 1-day White House pressure Wall Street has long expected the Trump administration to take some sort of action to put downward pressure on mortgage rates. But analysts are now wondering what the actual impact will be for consumers and what it means for lending stocks. "We read this as the President ordering FHFA Director Bill Pulte to force Fannie Mae and Freddie Mac to buy $200 billion of their own MBS to bring down interest rates," TD Cowen's Jaret Seiberg wrote to clients, referring to mortgage-backed securities. "This is not a surprise." TD Cowen expects the 10-year U.S. Treasury yield to finish 2026 at 3.5%, down from about 4.17% on Friday. That would put downward pressure on 30-ye...
Oklo's partnership with Meta on nuclear energy highlights its promising role in powering AI's future, with strong stock gains, speculative valuation, and analyst support making it an attractive buy for 2026.
Oklo's partnership with Meta on nuclear energy highlights its promising role in powering AI's future, with strong stock gains, speculative valuation, and analyst support making it an attractive buy for 2026.